Deep Track Capital

Zura Bio offers therapies for patients by incorporating immunology resources into phase 2 development programs, such as ZB-168 and torudokimab, with auto-immune illnesses. ZB-168 is an anti-IL7R inhibitor that may have an effect on disorders whose biological pathways are IL7 and TSLP. They create therapeutic indications for ZB-168 that build on the type 1 diabetes data from Phase 1b studies and show a profile and biological basis. The phase 2 clinical development stage of torudokimab, a human-affinity monoclonal antibody that neutralizes IL33, has been established.

TORL BioTherapeutics is a clinical-stage biopharmaceutical business focused on creating innovative, antibody-based medicines to improve the lives of cancer patients. They are developing a comprehensive pipeline of innovative preclinical ADCs and mAb in oncologic diseases with high unmet medical needs.

Valneva is a pharmaceutical company developing prophylactic vaccines to treat infectious diseases. The company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. Valneva has leveraged its expertise and capabilities both to commercialize two vaccines successfully and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus, and COVID-19.

Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, oral KIT inhibitor for treatment of severe allergy and inflammation. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with allergic diseases.

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines. Its platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins that make them accessible to small-molecule drug discovery and development.

Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose (SAD) clinical trial. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term.

Biotheryx is a clinical stage biopharmaceutical company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) for the treatment of a wide range of diseases with an initial focus on cancer. Members of our founding and scientific teams previously developed the first FDA approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and have applied their expertise in Cereblon binding to build our proprietary PRODEGY platform. Our platform leverages an extensive patent protected and rationally designed library of Cereblon binders that we believe provides us with a differentiated starting point for drug design of molecular glues, bifunctional degraders and hybrid degraders.

Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.